Literature DB >> 9733898

Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene.

S W Lee1, J H Cho, Y C Sung.   

Abstract

In this study, we have constructed various DNA vaccine vectors that carried hepatitis C virus (HCV) envelope genes without and with the granulocyte-macrophage colony-stimulating factor (GM-CSF) gene in several different ways. In Buffalo rats that received plasmids carrying the HCV envelope genes, which encode envelope proteins E1 and E2, both antibody and lymphoproliferative responses against these proteins were induced. These responses were greatly enhanced by the codelivery of the GM-CSF gene. In particular, inoculation with a bicistronic plasmid that independently expressed the GM-CSF gene and the envelope genes in the same construct generated the highest antibody titers and significantly increased lymphoproliferative responses against these proteins. Moreover, strong antibody responses to homologous and heterologous hypervariable region 1 peptides were elicited in the immunized rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733898      PMCID: PMC110238     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

Review 1.  New approaches to the treatment of chronic viral hepatitis B and C.

Authors:  F Regenstein
Journal:  Am J Med       Date:  1994-01-17       Impact factor: 4.965

2.  Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.

Authors:  Y H Chow; W L Huang; W K Chi; Y D Chu; M H Tao
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

3.  Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery.

Authors:  T M Pertmer; T R Roberts; J R Haynes
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

4.  Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines.

Authors:  Z Xiang; H C Ertl
Journal:  Immunity       Date:  1995-02       Impact factor: 31.745

5.  Vaccination of chimpanzees against infection by the hepatitis C virus.

Authors:  Q L Choo; G Kuo; R Ralston; A Weiner; D Chien; G Van Nest; J Han; K Berger; K Thudium; C Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

6.  Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients.

Authors:  B Rehermann; K M Chang; J McHutchinson; R Kokka; M Houghton; C M Rice; F V Chisari
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

7.  Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients.

Authors:  E Scarselli; A Cerino; G Esposito; E Silini; M U Mondelli; C Traboni
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

8.  Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment.

Authors:  A Zibert; E Schreier; M Roggendorf
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

9.  DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid.

Authors:  M E Major; L Vitvitski; M A Mink; M Schleef; R G Whalen; C Trépo; G Inchauspé
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Immune responses to plasmid DNA encoding the hepatitis C virus core protein.

Authors:  L M Lagging; K Meyer; D Hoft; M Houghton; R B Belshe; R Ray
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  15 in total

1.  Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.

Authors:  J Satoi; K Murata; M Lechmann; E Manickan; Z Zhang; H Wedemeyer; B Rehermann; T J Liang
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice.

Authors:  M K Song; S W Lee; Y S Suh; K J Lee; Y C Sung
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.

Authors:  Man Ki Song; Christofer J Vindurampulle; Alejandra V E Capozzo; Jeffrey Ulmer; John M Polo; Marcela F Pasetti; Eileen M Barry; Myron M Levine
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis.

Authors:  Giovanni Delogu; Amy Li; Charlene Repique; Frank Collins; Sheldon L Morris
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

5.  Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization.

Authors:  A Fournillier; E Depla; P Karayiannis; O Vidalin; G Maertens; C Trépo; G Inchauspé
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles.

Authors:  Ioanna Skountzou; Fu-Shi Quan; Sailaja Gangadhara; Ling Ye; Andrei Vzorov; Periasamy Selvaraj; Joshy Jacob; Richard W Compans; Sang-Moo Kang
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

Review 7.  Prevention of cervical cancer with vaccines.

Authors:  S S Im; B J Monk; L P Villarreal
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

8.  Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization.

Authors:  Jin-Won Youn; Su-Hyung Park; Jae Ho Cho; Young Chul Sung
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene.

Authors:  So Young Choi; You Suk Suh; Jae Ho Cho; Hyun Tak Jin; Jun Chang; Young Chul Sung
Journal:  Immune Netw       Date:  2009-10-30       Impact factor: 6.303

10.  GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.

Authors:  Lilin Lai; Dalma Vödrös; Pamela A Kozlowski; David C Montefiori; Robert L Wilson; Vicki L Akerstrom; Lakshmi Chennareddi; Tianwei Yu; Sunil Kannanganat; Lazarus Ofielu; Francois Villinger; Linda S Wyatt; Bernard Moss; Rama Rao Amara; Harriet L Robinson
Journal:  Virology       Date:  2007-08-14       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.